We examined the efficacy and efficiency of UFSHR, a novel synthetic derivative of YM155, in inhibiting survivin expression and in regulating both in vitro tumorigenic activities (including cell proliferation, apoptosis, migration) and in vivo tumor progression, using our primary pancreatic cancer lines (PPCLs) established from patient-derived tumor xenografts from primary PDAC tumors (PPCL-46) and hepatic metastases (PPCL-LM1) [34]. Here, BIRC5 is linked to neoplasm.